Loading...
•
Jun 30, 2021
Design Therapeutics Q2 2021 Earnings Report
Design Therapeutics reported GeneTAC™ portfolio progress and second quarter 2021 results.
Key Takeaways
Design Therapeutics reported a net loss of $7.6 million for the second quarter of 2021. The company's research and development expenses were $5.0 million, and general and administrative expenses were $2.7 million. As of June 30, 2021, the company had cash, cash equivalents and investment securities of $402.8 million.
New data from IND-enabling studies with GeneTAC product candidate for Friedreich Ataxia (FA) support initiation of clinical trial in first half of 2022.
The company is on-track for FA GeneTAC initiation of clinical trial in the first half of 2022.
Design Therapeutics has continued progress across GeneTAC portfolio with Myotonic Dystrophy with preclinical data to be reported in the second half of 2021.
Leadership team was strengthened with the appointment of Elizabeth Gordon, Ph.D. as Senior Vice President of Regulatory Affairs.